SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: 2020-03-02 | Period of Report: 2020-02-27 SEC Accession No. 0001127602-20-008630

(HTML Version on secdatabase.com)

REPORTING OWNER

Andres Juan

CIK:1760670 Type: 4 | Act: 34 | File No.: 001-38753 | Film No.: 20678016

ISSUER

Moderna, Inc.

CIK:1682852| IRS No.: 813467528 | State of Incorp.:DE | Fiscal Year End: 1231 SIC: 2836 Biological products, (no disgnostic substances) Mailing Address C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139

Mailing Address	Business Address
200 TECHNOLOGY SQUARE	200 TECHNOLOGY SQUARE
CAMBRIDGE MA 02139	CAMBRIDGE MA 02139
	6177146500

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Expires:	02/28/2011								
Estimated average burden									
hours per response 0.5									

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address <u>Andres Juan</u>	of Reporting Person	-	2. Issuer Name and Ticker or Trading Symbol <u>Moderna, Inc.</u> [MRNA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/27/2020	Officer (give title Other (specify below) below) See remarks
C/O MODERNA, I	INC., 200 TECHN	OLOGY SQUARE		
(Street) CAMBRIDGE, MA 02139			4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing (Check applicable line) X Form Filed by One Reporting Person Form Filed by More than One Reporting Person
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/Year)	Execution Date, if any (Month/Day/			4. Securities Acc of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Year)	Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	
Common Stock	02/27/2020		<u>M</u> ⁽¹⁾		8,006	Α	\$12.21	8,006	D	
Common Stock	02/27/2020		<u>s</u> ⁽¹⁾		2,046	D	\$34.81 ⁽²⁾	5,960	D	
Common Stock	02/27/2020		<u>s</u> ⁽¹⁾		2,188	D	\$34.1 ^(<u>3</u>)	3,772	D	
Common Stock	02/27/2020		<u>s</u> ⁽¹⁾		3,272	D	\$33.05 ^(<u>4</u>)	500	D	
Common Stock	02/27/2020		<u>s</u> ⁽¹⁾		500	D	\$31.95 ^(<u>5</u>)	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Date, if any (Month/ Day/	4. Transa Code (Instr. 8	ction 3)	5. Number Derivative Securities Acquired (Disposed (Instr. 3, 4, 5)	A) or of (D)	Expiration Date (Month/Day/ Year)		Expiration Date (Month/Day/ Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
			Year)	Code	V	(A)	(D) Exercisable Date Expiration Date Title Shares			Transaction(s) (I) (Instr. (Instr. 4) 4)							
Stock Option (Right to Buy)	\$12.21	02/27/2020		<u>M</u> ⁽¹⁾			8,006	(<u>6</u>)	08/29/2027	Common Stock	8,006	\$ 0	909,425	D			
Stock Option (Right to Buy)	\$25.93	02/28/2020		A		161,120		02/28/2021 ^(Z)	02/28/2030	Common Stock	161,120	\$ 0	161,120	D			

Restricte Stock Units	¢d \$ 0	02/28/2020	A	28,924	02/28/2022 (8)	Common Stock	28,924	\$ 0	28,924	D	

Explanation of Responses:

- 1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$34.63 to \$35.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$33.62 to \$34.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$32.60 to \$33.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$31.59 to \$32.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 6. 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.
- 7. 25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
- 8. 50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.

Signatures

/s/ Lori Henderson, as Attorney-in-Fact	03/02/2020
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.